2. Search Result
Search Result
Results for "

Rapamycin Derivative

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

2

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10218
    Everolimus
    110+ Cited Publications

    RAD001; SDZ-RAD

    		 mTOR FKBP Autophagy Apoptosis Bacterial Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus
  • HY-12424
    Zotarolimus
    4 Publications Verification

    ABT-578; A 179578

    		 Drug Derivative Cardiovascular Disease Inflammation/Immunology Cancer
    Zotarolimus (ABT-578) is a derivative of Rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis .
    Zotarolimus
  • HY-136660
    PQR626

    		mTOR Neurological Disease
    PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant mTOR inhibitor, with an IC50 and Ki of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders .
    PQR626
  • HY-10218S
    Everolimus-d4

    RAD001-d4; SDZ-RAD-d4

    		 mTOR FKBP Autophagy Apoptosis Cancer
    Everolimus-d4 is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus-d4
  • HY-123691
    7-O-Demethyl rapamycin

    		Fungal Infection Inflammation/Immunology Cancer
    7-O-Demethyl rapamycin, a derivative of Rapamycin (HY-10219), has antifungal activity and immunosuppressant properties. 7-O-Demethyl rapamycin has useful tumor cell growth-inhibiting activity .
    7-O-Demethyl rapamycin
  • HY-10218R
    Everolimus (Standard)

    RAD001 (Standard); SDZ-RAD (Standard)

    		 Reference Standards mTOR FKBP Autophagy Apoptosis Bacterial Cancer
    Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus (Standard)
  • HY-122402
    Umirolimus

    		Bacterial Inflammation/Immunology
    Umirolimus, a macrocyclic triene lactone Rapamycin derivative, is powerful immunosuppressant and anti-inflammatory agent. Umirolimus has highly lipophilicity and can be used agent-eluting stent (DES) applications .
    Umirolimus
  • HY-142003
    27-O-Demethylrapamycin

    		Fungal Infection
    27-O-Demethylrapamycin, a Rapamycin (HY-10219) derivative, is an antifungal agent. 27-O-Demethylrapamycin inhibits Candida albicans, Saccharomyces cerevisiae, and Fusarium oxysporum .
    27-O-Demethylrapamycin
  • HY-135445
    Prolylrapamycin

    21-NorRapamycin

    		 Fungal Infection
    Prolylrapamycin (21-Norrapamycin) is the derivative of Rapamycin (HY-10219). Prolylrapamycin exhibits antifungal activity, that inhibits Candida albicans, Saccharomyces cerevisiae, and Fusarium oxysporum with MIC of 0.125-2 μg/mL .
    Prolylrapamycin
  • HY-122402S
    Umirolimus-d5

    		Isotope-Labeled Compounds Bacterial Inflammation/Immunology
    Umirolimus-d5 is the deuterium labeled Umirolimus (HY-122402). Umirolimus, a macrocyclic triene lactone Rapamycin derivative, is powerful immunosuppressant and anti-inflammatory agent. Umirolimus has highly lipophilicity and can be used agent-eluting stent (DES) applications .
    Umirolimus-d5
  • HY-106979
    Olcorolimus

    SAR-943

    		 Drug Derivative Interleukin Related Inflammation/Immunology
    Olcorolimus (SAR-943) is a Rapamycin (HY-10219) derivative. Olcorolimus can reduce IL-4, IL-5, eosinophil, neutrophil, lymphocyte, cellular fibronectin; lung epithelial cell proliferation and mucus hypersecretory phenotype in Ovalbumin (HY-W250978)-sensitized BALB/c mice. Olcorolimus can be used for the researches of inflammation and immunology, such as asthma .
    Olcorolimus
  • HY-10218S1
    Everolimus-13C2,d4

    RAD001-13C2,d4; SDZ-RAD-13C2,d4

    		 Isotope-Labeled Compounds Bacterial Autophagy FKBP mTOR Apoptosis Cancer
    Everolimus- 13C2,d4 (RAD001- 13C2,d4) is 13C labeled Everolimus. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
    Everolimus-13C2,d4
  • HY-133770
    Seco Rapamycin ethyl ester

    		Drug Metabolite Others
    Seco Rapamycin ethyl ester is an open-ring metabolite of Rapamycin derivative. Seco-rapamycin is reported not to affect the mTOR function .
    Seco Rapamycin ethyl ester
  • HY-132003
    Wortmannin-Rapamycin Conjugate 1

    		Akt Cancer
    Wortmannin-Rapamycin Conjugate 1 (compound 7c) is a furan ring-opened derivative of wortmannin-rapamycin conjugate with potent antitumor activities and a fine water solubility. Wortmannin-Rapamycin Conjugate 1 can inhibit the AKT phosphorylation in the tumor and can be used for cancer research .
    Wortmannin-Rapamycin Conjugate 1
  • HY-185200
    Rapamycin 42-hemisuccinate

    		Drug Derivative Others
    Rapamycin 42-hemisuccinate is a Rapamycin (HY-10219) derivative used in the synthesis of sterolated Rapamycin liposomes .
    Rapamycin 42-hemisuccinate
  • HY-181873
    Rapamycin-butyl ester

    Sirolimus-butyl ester

    		 Drug Derivative Cancer
    Rapamycin-butyl ester (Sirolimus-butyl ester) (Compound 9) is a derivative of Rapamycin (HY-10219). Rapamycin-butyl ester exhibits antiproliferative effects against liver cancer cells and renal cancer cells. Rapamycin-butyl ester can be used in research related to liver cancer and renal cancer .
    Rapamycin-butyl ester
  • HY-204504
    42-O-(2-Aminoethyl)-rapamycin

    		Drug Derivative Others
    42-O-(2-Aminoethyl)-rapamycin (compound 2.3) is a derivative of the mTOR inhibitor rapamycin. 42-O-(2-Aminoethyl)-rapamycin can be used in pharmaceutical research for developing conjugates .
    42-O-(2-Aminoethyl)-rapamycin
  • HY-180123
    42-O-(2-Azidoethyl)-Rapamycin

    		Drug Intermediate Infection
    42-O-(2-Azidoethyl)-Rapamycin (Compound 4) is an azide compound that can be used as a drug intermediate to synthesize the derivative of Rapamycin (HY-10219) .
    42-O-(2-Azidoethyl)-Rapamycin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: